- United States
- /
- Medical Equipment
- /
- NYSE:TFX
Here's What Analysts Are Forecasting For Teleflex Incorporated (NYSE:TFX) After Its Third-Quarter Results
Teleflex Incorporated (NYSE:TFX) shareholders are probably feeling a little disappointed, since its shares fell 9.6% to US$211 in the week after its latest third-quarter results. Teleflex reported in line with analyst predictions, delivering revenues of US$764m and statutory earnings per share of US$2.36, suggesting the business is executing well and in line with its plan. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Teleflex after the latest results.
Check out our latest analysis for Teleflex
Taking into account the latest results, the most recent consensus for Teleflex from 15 analysts is for revenues of US$3.24b in 2025. If met, it would imply a satisfactory 7.0% increase on its revenue over the past 12 months. Per-share earnings are expected to surge 105% to US$10.50. In the lead-up to this report, the analysts had been modelling revenues of US$3.28b and earnings per share (EPS) of US$10.74 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.
It might be a surprise to learn that the consensus price target was broadly unchanged at US$247, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Teleflex analyst has a price target of US$285 per share, while the most pessimistic values it at US$225. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Teleflex's growth to accelerate, with the forecast 5.6% annualised growth to the end of 2025 ranking favourably alongside historical growth of 3.9% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 8.3% annually. So it's clear that despite the acceleration in growth, Teleflex is expected to grow meaningfully slower than the industry average.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Teleflex. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Teleflex's revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$247, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Teleflex analysts - going out to 2026, and you can see them free on our platform here.
We don't want to rain on the parade too much, but we did also find 1 warning sign for Teleflex that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Teleflex might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:TFX
Teleflex
Designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
Excellent balance sheet and good value.